Donald A. Mcclain, MD, PhD

Professor, Endocrinology and Metabolism Academic Research Organization Translational Science Institute

Donald A. Mcclain, MD, PhD

Professor, Endocrinology and Metabolism
Director, Academic Research Organization
Associate Director, Translational Science Institute

About Me

Education Program Involvement

Molecular Medicine and Translational Science PhD
Program Research Interest: Analytical approaches to molecular and cellular synthesis, structure and function, Genetics and gene regulation, Cell communications, Organ systems, Pathophysiology

Education: BA, Haverford College, 1973; MD, PhD, Rockefeller University, 2015
Internship: Internal Medicine, Stanford University Hospital, 1983
Residency: Internal Medicine, Stanford University Hospital, 1985
Fellowship: Internal Medicine, University of California - San Diego, 1987
Board Certifications: American Board of Internal Medicine, Endocrinology, Diabetes and Metabolism; American Board of Internal Medicine, Internal Medicine
Memberships: American Association of Physicians & Surgeons; American Diabetes Association; American Federation of Clinical Research; Endocrine Society; American Society of Clinical Investigation; Western Association of Physicians
Positions: Professor, Endocrinology and Metabolism; Director, Academic Research Organization; Associate Director, Translational Science Institute
Departments and Affiliations: Endocrinology and Metabolism; Academic Research Organization; Translational Science Institute

Research

Publications

Adipose Tissue Transferrin and Insulin Resistance. McClain DA, Sharma NK, Jain S, Harrison A, Salaye LN, Comeau ME, Langefeld CD, Lorenzo FR, Das SK. J. Clin. Endocrinol. Metab. 2018 Nov; 103(11):4197-4208.
Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G. Leuk. Lymphoma. 2018 08; 59(8):1871-1877.
Synergistic Inhibitory Effects of Hypoxia and Iron Deficiency on Hepatic Glucose Response in Mouse Liver. Nam H, Jones D, Cooksey RC, Gao Y, Sink S, Cox J, McClain DA. Diabetes. 2016 06; 65(6):1521-33.
Mechanisms Linking Glucose Homeostasis and Iron Metabolism Toward the Onset and Progression of Type 2 Diabetes. Fernández-Real JM, McClain D, Manco M. Diabetes Care. 2015 Nov; 38(11):2169-76.
Adipocyte iron regulates leptin and food intake. Gao Y, Li Z, Gabrielsen JS, Simcox JA, Lee SH, Jones D, Cooksey B, Stoddard G, Cefalu WT, McClain DA. J. Clin. Invest. 2015 Sep; 125(9):3681-91.

View More Publications

Research Interests

BRCA1 Protein
Effects of Dietary Iron on Diabetes Risk
Hexosamines
Hypoxia and Metabolism
Metabolic Signaling by the Hexosamine Biosynthesis Pathway Mediated by Protein O-linked Glycosylation
Prevalence and Mechanism of Diabetes in Hereditary Hemochromatosis
Structure and Function of the Insulin Receptor

More Resources

More Resources

Donald A. Mcclain, MD, PhD

Donald A. Mcclain, MD, PhD

About Me

Education Program Involvement